Pmdi.Pk
PMDI.PK operates in the healthcare sector, specifically in the pharmaceuticals activity, and generates revenue through its operations in healthcare facilities and services.
Business. PMDI.PK operates in the healthcare sector, specifically in the pharmaceuticals activity, and generates revenue through its operations in healthcare facilities and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PMDI.PK operates in the healthcare sector, specifically in the pharmaceuticals activity, and generates revenue through its operations in healthcare facilities and services.
PMDI.PK has a liquidity position characterized by $1.42 million in cash and equivalents, with a current ratio of 1.82, indicating a relatively strong ability to meet short-term obligations. However, the company reported negative operating income of $1.895 million and a net loss of $1.861 million, which suggests operational challenges. The company's debt-to-equity ratio is 0.06, indicating a low level of leverage and a conservative capital structure.
In terms of profitability, PMDI.PK's return on equity is -36.28%, and its return on assets is -22.37%, both significantly below the industry median for healthcare facilities and services. These metrics suggest that the company is not generating returns that meet the expectations of its equity and asset base.
The company's revenue is concentrated in a single segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if its primary market experiences downturns.
PMDI.PK's growth trajectory is uncertain, as the company reported a net loss and negative operating income. There are no provided outlook figures for the current or next fiscal year, and the available data does not include historical revenue growth rates to assess long-term trends.
The risk assessment for PMDI.PK indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash position support the low liquidity risk rating. However, the negative operating and net income suggest potential operational risks that could affect future liquidity.
Recent events, including filings and transcripts, are not detailed in the available data. The company's financial snapshot does not include specific recent events or disclosures that would provide insight into its current strategic or operational direction.
- PMDI.PK has a strong liquidity position with a current ratio of 1.82 and $1.42 million in cash and equivalents.
- The company is currently unprofitable, with a net loss of $1.861 million and a return on equity of -36.28%.
- PMDI.PK maintains a conservative capital structure with a low debt-to-equity ratio of 0.06.
- The company's revenue is not diversified across segments or geographies, increasing its exposure to market-specific risks.
- There are no immediate liquidity or dilution risks, but the company's negative operating and net income suggest ongoing operational challenges.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PMDI.PK Market data — financials · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$0M
Leadership
- Brian HullingerPresident, Chief Executive Officer, Director
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Capex (YoY) (2024-12-31 vs 2023-12-31): -67.5%Derived (calculated)
- Cash & equivalents (YoY) (2024-12-31 vs 2023-12-31): -27.9%Derived (calculated)
- Operating income (YoY) (2024-12-31 vs 2023-12-31): 35.2%Derived (calculated)
- Total liabilities (YoY) (2024-12-31 vs 2023-12-31): -43.6%Derived (calculated)
- Cost of revenue (YoY) (2024-12-31 vs 2023-12-31): -8.0%Derived (calculated)
- Operating cash flow (YoY) (2024-12-31 vs 2023-12-31): 162.8%Derived (calculated)
- Total assets (YoY) (2024-12-31 vs 2023-12-31): -32.5%Derived (calculated)
- Gross profit (YoY) (2024-12-31 vs 2023-12-31): -15.6%Derived (calculated)
- Net income (YoY) (2024-12-31 vs 2023-12-31): 55.2%Derived (calculated)
- Return on assets (FY 2024-12-31): -22.4%Derived (calculated)
- Return on equity (FY 2024-12-31): -36.3%Derived (calculated)
- Current ratio (FY 2024-12-31): 1.82xDerived (calculated)
- Debt-to-equity (FY 2024-12-31): 0.62xDerived (calculated)
- R&D expense (YoY) (2024-12-31 vs 2023-12-31): -34.5%Derived (calculated)
- Shareholders' equity (YoY) (2024-12-31 vs 2023-12-31): -23.1%Derived (calculated)
- EPS (basic) (YoY) (2024-12-31 vs 2023-12-31): 55.6%Derived (calculated)
- R&D expense (annual): USD 749KSEC XBRL filing
- Current assets (annual): USD 4.94MSEC XBRL filing
- Operating cash flow (annual): USD 929KSEC XBRL filing
- Cash & equivalents (annual): USD 1.42MSEC XBRL filing
- Cost of revenue (annual): USD 12.58MSEC XBRL filing
- Total liabilities (annual): USD 3.19MSEC XBRL filing
- Shares outstanding (annual): 6.11MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing